Skip to search formSkip to main contentSkip to account menu

PTK787/ZK 222584

Known as: PTK787/ZK-222584, PTK787/ZK222584 
National Institutes of Health

Related topics

Related topics

4 relations
CGP79787DPTK 787Vascular Endothelial Growth Factor A

Broader (1)

vatalanib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib)
The phase III CONFIRM clinical trials demonstrated that metastatic colorectal cancer patients with elevated serum lactate… 
2010
2010
Phase 1‐2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma
This phase 1‐2 trial assessed the efficacy and tolerability of an oral angiogenesis inhibitor—PTK787/ZK222584 (PTK)—in… 
2009
2009
PTK787/ZK 222584 inhibits tumor growth promoting mesenchymal stem cells: Kinase activity profiling as powerful tool in functional studies
Bone marrow (BM)-derived mesenchymal stem cells (MSCs) have been shown to favour tumor growth, suggesting the relevance of… 
2007
2007
The Synergistic Action of a VEGF‐Receptor Tyrosine‐Kinase Inhibitor and a Sensitizing PDGF‐Receptor Blocker Depends upon the Stage of Vascular Maturation
Objective: To investigate the effects of tyrosine‐kinase inhibitors of vascular endothelial growth factor (VEGF) and platelet… 
Highly Cited
2005
Highly Cited
2005
PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits…
Assessment of tumour vascularity may characterize malignancy as well as predict responsiveness to anti‐angiogenic therapy. Non… 
2005
2005
A phase IB, open label, safety and pharmacokinetic (PK) study of escalating doses of PTK787/ZK 222584 (PTK/ZK) in combination with paclitaxel and carboplatin in patients (Pts) with stage IC to IV…
5075 Background: Vascular endothelial growth factors (VEGFs) and VEGF receptors (VEGFRs) are important mediators of tumor growth… 
Highly Cited
2004
Highly Cited
2004
A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM).
1513 Background: VEGF-mediated signaling through VEGF receptors is integral to GBM neovascularization and therefore an attractive… 
Highly Cited
2004
Highly Cited
2004
Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer.
3558 Background: Increased angiogenesis is correlated with poor prognosis in patients with advanced metastatic colorectal cancer… 
2004
2004
Phase I study of the novel, oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK): Evaluating the pharmacokinetic effect of a high-fat meal in patients with hormone-refractory prostate cancer (HRPC)
4689 Background: PTK/ZK is a novel, oral angiogenesis inhibitor that potently inhibits all known VEGF receptors, important… 
Review
2003
Review
2003
Soluble markers for the detection of hypoxia under antiangiogenic treatment.
Antiangiogenic therapy is a promising new strategy to inhibit tumor growth and formation of metastases. VEGF (vascular… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)